US › Healthcare

Generate Biomedicines, Inc. Common Stock (GENB)

US · Healthcare · Biotechnology

$14.28-0.42%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$7.2M

Net profit

$-61.4M

EPS

$-1.07

EPS estimate

$-0.51

Net margin

-850.6%

EPS came in at -1.07 against a street estimate of -0.51 — a miss of 109.8%.

Key statistics

Market cap

$1.79B

Forward P/E

0.0

P/B

3.49

Book value

$4.02

EPS (TTM)

$-2.07

52-week high

$18.18

52-week low

$11.00

50-day MA

$14.27

200-day MA

$13.51

Analyst view

with an average price target of $25.40.

Shareholding

Insiders

14.07%

Institutions

76.11%

Largest institutional holders

Fund	Stake
Flagship Ventures Management, Inc.	48.89%
FMR Inc	3.29%
Capital World Investors	3.12%
BRAIDWELL LP	2.80%
JPMorgan Chase & Co	2.30%
T. Rowe Price Associates, Inc.	1.65%
ARCH VENTURE CORP	1.52%
Harbourvest Partners, LLC	1.34%

Recent filings & reports

Document	Date
Quarterly report · Q1 2026	2026-05-07
Results announced · Q2 2026	2026-05-07
Charter / bylaws change · Q1 2026	2026-03-02

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Generate Biomedicines, Inc. Common Stock — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.